Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis

Launched by KEYMED BIOSCIENCES CO.LTD · Jan 27, 2023

Keywords

ClinConnect Summary

This study includes screening, treatment and follow-up periods. 160 subjects will be enrolled to receive CM310.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Have the ability to understand the study and voluntarily sign a written ICF.
• • Age ≥ 18 and ≤ 75 years old, male or female.
• • The fertile subjects agreed to take effective contraceptive measures throughout the study period.
• • The subjects can communicate well with the investigators and complete the follow-up according to the protocol.
• Exclusion Criteria:
• • Live vaccine or attenuated live vaccine has been vaccinated or planned to be vaccinated within 12 weeks before randomization.
• • He received allergen-specific immunotherapy (desensitization therapy) within 6 months before randomization.
• • Major surgery is planned during the study period.
• • Previous history of atopic keratoconjunctivitis and corneal involvement.
• • Other combined skin diseases that may affect the evaluation of the study.
• • Confronting IL-4R α Monoclonal antibody or CM310/placebo drug or ingredient allergy.